MedWatch

Top picks in English

Sydbank positive despite muted growth for Darzalex

Partner J&J's interim report shows that sales of Genmab’s cancer drug Darzalex doubled in Q3. However, the growth rate is lower compared to earlier this year, whivh has caused a drop in Genmab's share price. But despite the cancer hope’s failure to meet expectations, Sydbank still calls the development positive.

Lundbeck initiates two phase III studies with its main growth driver

Danish drug group Lundbeck and its Japanese partner Otsuka have started enrolling patients in two global phase III studies with the major engine of growth in the Danes’ new drugs portfolio. But neither analysts nor Lundbeck itself attach much importance to the development.

Danish life science company goes public in Sweden

The Danish company 2curex has announced its arrival on Nasdaq First North in Stockholm. According to the CEO, the reason is not lack of money; the timing is simply right for the company behind the IndiTreat-technology used to identify the most effective medical treatment for cancer patients.

New generic could put pressure on Veloxis

A generic version of the main competitor to Veloxis’ Envarsus XR will soon enter the European market and it could potentially pose a threat to the Danish biotech company’s key asset.

Bavarian announces name of RSV-partner

In September, Bavarian Nordic announced a new collaboration with a global contract research organization (CRO) on clinical trials with Bavarian’s RSV vaccine. The name of the new partner is now announced.

Analyst: new hearing patch can challenge the established market

A new product from Austrian company Med-El can replace a special hearing device solution that traditionally requires surgery – a market dominated by companies like the Denmark's William Demant. The Danish hearing aid giant must seriously consider the competition, says Sydbank analyst.

Zealand initiates new study with SBS drug

Danish biotech Zealand Pharma has initiated a new clinical trial with a long-acting version of its GLP-2 analogue glepaglutide against short bowel syndrome. The company expects to take the candidate to phase III in 2018.

Ambu CEO: We are in a good position for acquisitions

If Ambu is to meet its ambitious growth target – a revenue of DKK 5 billion (about USD 786 million) by 2020 – the company must make acquisitions. “I have a list of 10 companies,” says Ambu’s CEO, who will use a strategy different from the competitors’.

Sweden believes in EMA candidacy despite criticism

The European Medicines Agency (EMA) is highly critical of the Swedish bid to house the agency when it leaves London. The rejection is based on an evaluation of the buildings in Stockholm planned to be the new headquarters of EMA. The Swedish EMA-ambassador calls the critique “misleading”.

Novo-owned company sells former Boehringer project

The Swedish drug group Orexo, in which Novo Holdings holds one fourth of the shares, has sold a development program for anti-inflammatory drugs to a newly founded company in Stockholm. Orexo also appoints Novo Holdings CEO Kasim Kutay as head of its nomination committee.

Genmab begins phase II trial with pipeline hope

Within the first half of 2018, the biotech company Genmab plans to treat the first patient with cervical cancer in a new study of the drug tisotumab vedotin. The study provides opportunity for an accelerated approval process.

Novo Holdings prepares for major US offensive

Danish investment company Novo Holdings is planning to make more major investments in the US. The board has not made an official decision yet, but the plans will likely entail adding more employees to the company’s current office in Boston, says CEO Kasim Kutay.

New vaccine contract paves the way for Bavarian in the US

The US Department of Health has awarded a million-dollar contract on smallpox vaccines to Bavarian Nordic and thus confirmed the collaboration between the Danish company and the US government, according to chief financial officer, Ole Larsen. This is also good news for the company’s freeze-dried version of the vaccine.

Former Zealand chief ready for phase III studies in new company

He managed Zealand Pharma until 2015 and now David Solomon has taken the reins in a US-based biotech company preparing for pivotal phase III studies of its key asset next year. When the drug enters the market it will compete with one of the world’s most expensive therapies.

Ambu CEO takes Swedish rehab company public

The Swedish company Handicare is on the brink of carrying out the biggest IPO of a medtech company globally this year. It aims to raise at least 70 million dollars to continue the company’s international expansion, says Ambu CEO Lars Marcher, who is also chairman of the board in Handicare.

Onxeo shows good pre-clinical results for cancer combo

French-Danish biotech company Onxeo has presented good pre-clinical data for the combination of two of its cancer drugs, one of which is developed by Danish Topotarget, on various tumor cell lines. The company has filed a patent application for the possible combination treatment.

Medtech listings in clover in Sweden

Swedish markets account for half of the biggest global IPO’s of medtech companies in the first half of 2017, according to a new report from EvaluateMedtech. A Lundbeck Foundation portfolio company has carried out the by far biggest IPO this year.

Analyst: Bavarian failure was no surprise

The market should not have been caught off guard by Bavarian Nordic’s failed Prostvac trial, says analyst Peter Aabo. The trial was not designed properly from the beginning.